CME and CFTC Clash Over On-Chain Perpetual Futures

The CME Group, the largest derivatives exchange operator in the US, is locked in a bitter dispute with its regulator, the Commodity Futures Trading Commission (CFTC), over the introduction of blockchain-based perpetual futures products. The CFTC's decision to allow the listing of these products, also known as 'perps', has been met with resistance from the CME, which claims that the regulator is mislabeling them and misapplying the law. The CME argues that perps are harmful to its traditional futures products and that the CFTC's approval of them did not consider the potential consequences. The dispute has significant implications for the rapidly growing market of perpetual futures, with non-US perps volume reportedly reaching $60 trillion in volume last year. The CFTC's approval of perps has been seen as a major shift in the regulator's approach to the crypto market, and the CME's lawsuit challenging the decision is being closely watched by industry participants. The case is likely to have a significant impact on the development of the US crypto market and the role of regulators in shaping its future. The CME's chairman, Terry Duffy, has been a vocal critic of the CFTC's approach, arguing that the regulator is not following the proper procedures and that the introduction of perps could lead to unintended consequences. The dispute has also sparked a wider debate about the role of regulators in the crypto market and the need for clearer guidelines and rules to govern the development of new products and technologies.